Scientific deep-dive
Does Kaiser Permanente Cover Weight Loss Drugs? Honest Coverage Review
It depends on your region and plan tier. Kaiser covers type 2 diabetes GLP-1s with internal prior authorization, but weight-management coverage of Wegovy, Zepbound and Saxenda varies, and large employers often exclude it. KP Medi-Cal in California dropped them Jan 1, 2026.
Short version: Kaiser Permanente is an integrated HMO that runs its own pharmacies and its own formulary committees, so coverage of weight-loss drugs is decided regionally and is heavily plan-tier dependent. The VA also runs its own pharmacies and national formulary, and it keeps weight-loss GLP-1s non-formulary. GLP-1s for type 2 diabetes (Ozempic, Mounjaro, Trulicity, Victoza) are widely covered across KP regions with prior authorization. GLP-1s for chronic weight management (Wegovy, Zepbound, Saxenda) are covered on some KP plans and excluded on others — the decision tracks region (CA, CO, OR, WA, HI, MD, VA, GA, DC) and employer tier. KP Senior Advantage Medicare members face the same federal Part D weight-loss exclusion as every other Medicare plan.
Before relying on the Saxenda rules below, note that Novo Nordisk is discontinuing Saxenda, with final wholesaler shipments in late January 2027 (notice checked November 2026). FDA-approved generic liraglutide 3 mg exists, and your prescriber can advise on a replacement.
The honest answer
It depends on your region and your specific plan tier. In California, Kaiser's largest market, commercial and Individual & Family plans renewing on or after January 1, 2025 no longer cover GLP-1s prescribed only for weight loss when BMI is under 40; large employers can add that coverage back with a weight-loss drug rider. Outside California, coverage depends on the region's formulary and the employer's plan design, and many large-employer KP plans carve weight-loss drugs out entirely. Carve-outs are common elsewhere too, including at Blue Cross Blue Shield, where some plans dropped weight-loss GLP-1s in 2025 and 2026. KP Senior Advantage (Medicare Advantage) does NOT cover weight-loss-only AOMs under federal exclusion. KP Medi-Cal in California stopped covering weight-loss GLP-1s on January 1, 2026. Always verify with your specific KP plan, group, and region before committing.
At a glance
- KP GLP-1 coverage for type 2 diabetes: generally YES with PA across all eight KP regions. Ozempic, Mounjaro, Trulicity, and Victoza are on most KP formularies for the diabetes indication.[1]
- KP GLP-1 coverage for chronic weight management: varies. California commercial and Individual & Family plans dropped weight-loss-only coverage below BMI 40 starting with January 2025 renewals[12]. Some other KP commercial plans cover Wegovy or Zepbound with PA; others (especially large-employer-funded plans) exclude AOMs as a benefit class. Verify on your specific plan's formulary.
- KP Senior Advantage (Medicare Advantage): NO for weight-loss-only Wegovy/Zepbound/Saxenda — federal Part D excludes “agents when used for the symptomatic relief of cough and colds, anorexia, weight loss, or weight gain.”[2] YES for the Zepbound OSA indication post-12/20/2024 FDA approval.[6]
- KP Medi-Cal (California): weight-loss GLP-1 coverage was removed from the Medi-Cal Rx list of covered drugs effective January 1, 2026. KP Medi-Cal subscribers are affected by the same statewide exclusion. See our California Medi-Cal GLP-1 coverage article for the full carve-out.
- KP FEHB (federal employees): coverage decisions are made at the OPM-approved carrier level. Some KP FEHB regional plans cover Wegovy/Zepbound with PA; others exclude. Federal employees should request the KP FEHB region's Summary of Benefits and Coverage (SBC). [4]
- Typical PA pattern: KP PA requests are internal — your KP primary-care physician submits via KP HealthConnect (the Epic-based EHR), not via an external PBM portal. Turnaround is typically 5-10 business days.
- Cost when covered: typical KP copay tiers place GLP-1s on Tier 3 (preferred brand) or Tier 4 (non- preferred brand). Out-of-pocket after PA approval is generally $25-$100/month, depending on the plan tier.
Why Kaiser is structurally different from Aetna or Anthem
Most American health plans are PBM-administered — Aetna runs prescriptions through CVS Caremark, Anthem through CarelonRx, UnitedHealthcare through OptumRx. The plan's formulary is published by the PBM, prior authorization is adjudicated by the PBM, and members fill prescriptions at retail pharmacies (CVS, Walgreens, etc.) that submit claims back to the PBM.
Kaiser Permanente works differently. It's a fully integrated HMO with three interlocking pieces:[11]
- Kaiser Foundation Health Plan — the insurance arm that contracts with employers and individual members.
- Kaiser Foundation Hospitals + KP outpatient facilities — KP owns and operates its own hospitals, medical offices, and Kaiser Permanente Pharmacy locations (mostly co-located inside KP medical buildings).
- The Permanente Medical Groups — physician groups whose doctors are salaried KP employees (not fee-for-service). The largest are The Permanente Medical Group (TPMG) in Northern California and Southern California Permanente Medical Group (SCPMG).
Three practical implications for weight-loss drug coverage:
- KP's formulary committee is internal. KP Drug Use Management committees decide which GLP-1s land on which tier and which require PA. There is no external PBM negotiating rebates that drive Wegovy-vs-Zepbound preferred-product designations like CarelonRx or CVS Caremark do on commercial plans.
- Prescriptions fill at KP pharmacies, not retail. When a KP-affiliated physician prescribes Wegovy or Zepbound, the prescription routes to a Kaiser Permanente Pharmacy by default. Out-of-network retail (CVS, Walgreens) is generally not a covered benefit on standard KP HMO plans.
- The prescriber is on salary, not bonus. Permanente physicians are not incentivized by prescription volume or by which brand they pick. That removes one source of bias commonly seen in fee-for-service environments but also means KP physicians follow internal KP clinical guidelines closely.
GLP-1 coverage for type 2 diabetes (widely covered)
Across all eight KP regions, GLP-1 receptor agonists for the type 2 diabetes indication are generally on-formulary with prior authorization. The agents commonly covered:
- Ozempic (semaglutide) — once-weekly injection, FDA-approved for T2D + cardiovascular risk reduction in T2D with established CVD.
- Mounjaro (tirzepatide) — once-weekly dual GIP/GLP-1, FDA-approved for T2D.
- Trulicity (dulaglutide) — once-weekly GLP-1, FDA-approved for T2D + CV risk reduction.
- Victoza (liraglutide) — daily GLP-1, FDA-approved for T2D; older agent with both branded and authorized-generic forms.
- Rybelsus (oral semaglutide) — daily oral tablet, FDA-approved for T2D.
Typical KP PA criteria for a T2D GLP-1: a confirmed T2D diagnosis (ICD-10 E11.x), a documented A1C measurement, usually a trial of metformin (or documented metformin intolerance/contraindication), and prescriber documentation of treatment goals. The PA is submitted internally by the prescribing KP physician through KP HealthConnect.
GLP-1 coverage for chronic weight management (varies by region)
This is where Kaiser becomes complicated. The three FDA-approved anti-obesity GLP-1s — Wegovy (semaglutide 2.4 mg, indication: chronic weight management in adults + pediatric patients aged 12+ with obesity per DailyMed SetID ee06186f-2aa3-4990-a760-757579d8f77b[5]), Zepbound (tirzepatide, indication: chronic weight management + moderate-to-severe OSA in adults with obesity per DailyMed SetID 487cd7e7-434c-4925-99fa-aa80b1cc776b [6]), and Saxenda (liraglutide 3.0 mg) — are covered on some KP commercial plans and excluded on others. The biggest exclusion is in California: for contracts renewing on or after January 1, 2025, base commercial and Individual & Family plans stopped covering these drugs when they are prescribed solely for weight loss in patients with a BMI under 40, while coverage for a BMI of 40 or higher, and for disease-management uses such as type 2 diabetes, stayed in place[12].
The decision tracks two axes:
- Region. KP operates as semi-autonomous regional health plans: KP Northern California, KP Southern California, KP Colorado, KP Northwest (Oregon + SW Washington), KP Washington, KP Hawaii, KP Mid-Atlantic States (Maryland + Virginia + DC), and KP Georgia. Each region's formulary committee maintains its own formulary edition. A drug covered in KP NorCal commercial may be excluded in KP Georgia commercial, or vice versa. Use the regional formulary search at kp.org/formulary.[1]
- Employer plan tier. KP sells multiple benefit designs to employers, from minimal-formulary HMO products through premium plans that include AOM coverage. Some large-employer KP groups (notably federal employees via FEHB, plus certain large private employers) negotiate AOM inclusion as a benefit-rider. Other employer groups actively choose to exclude AOMs to control premium cost.
Typical KP commercial PA criteria when the plan does cover AOMs: BMI ≥ 30 kg/m², OR BMI ≥ 27 with a weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, or — post-12/20/2024 for Zepbound — moderate-to-severe obstructive sleep apnea), age 18 or older, and documentation of a behavioral and dietary intervention. For the underlying weight-loss magnitudes that anchor PA decisions, see our Wegovy-to-Zepbound dose equivalence guide.
California Kaiser Permanente Medi-Cal and the 2026 reversal
California Medi-Cal (the state Medicaid program) removed Wegovy, Zepbound, and Saxenda from the list of covered drugs for the weight-loss indication effective January 1, 2026. The carve-out was driven by Medi-Cal Rx (the state's carved-out pharmacy benefit), not by individual managed-care plans. KP Medi-Cal members in California fall under the same statewide exclusion — there is no KP-specific carve-back-in for weight-loss-only GLP-1 use.
Two important nuances:
- T2D coverage is unaffected. Medi-Cal continues to cover Ozempic, Mounjaro, Trulicity, and Victoza for the type 2 diabetes indication. KP Medi-Cal members with T2D can still receive a GLP-1 through the standard Medi-Cal Rx pathway.
- Cardiovascular-risk indication is also unaffected. Wegovy retains a separate FDA-approved indication for cardiovascular risk reduction in adults with established CVD and overweight/obesity (per DailyMed SetID ee06186f-2aa3-4990-a760-757579d8f77b[5]). That indication is distinct from weight loss and the Medi-Cal carve-out does not block it.
For the full Medi-Cal mechanics and how the carve-out interacts with KP's integrated model, see our California Medi-Cal GLP-1 coverage article.
KP Senior Advantage (Medicare Advantage) — federal exclusion
KP Senior Advantage is Kaiser's Medicare Advantage HMO product (MA-PD). Like every Medicare Part D plan in the country, it operates under Social Security Act §1860D-2(e)(2)(A), which explicitly excludes “agents when used for the symptomatic relief of cough and colds, anorexia, weight loss, or weight gain” from Part D coverage.[2] This is a federal statutory exclusion — KP Senior Advantage cannot cover Wegovy, Zepbound, or Saxenda for weight-loss-only indications regardless of how much medical necessity is documented. Humana's Medicare members hit that wall too.
Three exceptions where KP Senior Advantage CAN cover otherwise-excluded GLP-1s:
- Ozempic / Mounjaro / Trulicity for T2D. T2D is not a weight-loss indication, so the §1860D-2(e)(2)(A) exclusion does not apply.
- Zepbound for moderate-to-severe obstructive sleep apnea. The FDA approved this distinct indication on December 20, 2024. The Zepbound label (SetID 487cd7e7- 434c-4925-99fa-aa80b1cc776b[6]) lists OSA in adults with obesity as a separately FDA-approved indication — and because it's not weight loss, the Part D exclusion does not block coverage. KP Senior Advantage can cover Zepbound for OSA subject to internal PA. The SURMOUNT-OSA trial is the underlying evidence base.[10]
- Wegovy for cardiovascular risk reduction. Wegovy's second FDA-approved indication is reducing the risk of major adverse cardiovascular events in adults with established CVD and overweight/obesity. As a non-weight-loss indication, this is technically coverable on Medicare Part D — though individual KP Senior Advantage formularies vary on how aggressively they cover it. Confirm with your KP regional formulary.
KP Federal Employees Health Benefits (FEHB) plans
Kaiser participates in the federal employees' health program in every region where KP operates. KP FEHB plans follow OPM's prescription-drug benefit standards, which require coverage of medically necessary FDA-approved drugs but leave AOM coverage decisions to the carrier and the plan-type tier (HDHP vs Standard vs High Option).[4]
In practice, KP FEHB anti-obesity coverage tracks the same region-by-region pattern as commercial: some KP FEHB regional plans cover Wegovy/Zepbound with PA on the Standard or High Option tier; some restrict AOMs to T2D-comorbidity documentation only; some exclude AOMs from the prescription benefit entirely. Federal employees should request the KP FEHB SBC for their specific region directly from OPM's plan brochures.[4]
Magnitude comparison
Typical monthly out-of-pocket cost for weight-loss GLP-1s by Kaiser Permanente pathway. The KP commercial-with-PA-approved tier is the cheapest covered option; KP Senior Advantage Medicare members face the federal Part D exclusion and need to look at cash-pay or the Zepbound OSA / Wegovy CVD indication carve-ins. Cash-pay floor via LillyDirect Self Pay vials sits well below brand-retail.[1][5][6]
- KP commercial — PA approved, Tier 3 preferred brand25 $/molowest covered path
- KP commercial — PA approved, Tier 4 non-preferred75 $/mo
- KP Senior Advantage — Zepbound for OSA indication100 $/moOSA only; not weight loss
- KP commercial — AOM excluded (employer carve-out)0 coveredZero on this scaleself-pay only
- LillyDirect Self Pay vial — 2.5 mg starting dose299 $/mo
- LillyDirect Self Pay vial — 7.5 mg therapeutic499 $/mo
- LillyDirect Self Pay vial — 10/12.5/15 mg699 $/mo
- Retail brand Wegovy/Zepbound autoinjector cash1,300 $/moworst case
- Compounded tirzepatide — 503A telehealth250 $/monot brand Zepbound
How to find out if YOUR Kaiser plan covers Wegovy or Zepbound
Four reliable ways, in order from fastest to most authoritative:
- kp.org member portal → Coverage → Drug Formulary Search. Sign in, select your region and plan, search for “Wegovy” or “Zepbound” and the result will indicate the tier and whether prior authorization is required. This is the canonical source for your specific plan's formulary.[1]
- Phone KP Member Services. Regional numbers are printed on the back of your KP member card. Ask specifically: “Does my plan cover (drug name) for chronic weight management? What is the copay tier and the PA requirement?”
- Ask your KP primary-care physician. KP PCPs have direct access to the regional formulary via KP HealthConnect and can confirm at the point of care. Because KP physicians are salaried, there is no financial incentive for the PCP to push a drug your plan doesn't cover.
- Request the Evidence of Coverage (EOC) document. The EOC is the legal contract describing exactly what's covered. AOM exclusions, if present, will be listed in the excluded benefits section. For employer-sponsored plans, HR or the benefits administrator can provide the EOC.
Prior authorization process at Kaiser (different from commercial)
Because KP is integrated, the PA process is internal — there is no third-party PBM portal. The typical flow:
- The KP physician evaluates the patient against KP's internal AOM clinical-decision-support guidance (BMI ≥30, or ≥27 with a weight-related comorbidity, plus behavioral program documentation in the case of Wegovy/Zepbound).
- If criteria are met, the physician submits a PA request directly through KP HealthConnect (the KP-customized Epic EHR). No external fax to a PBM, no external portal.
- KP's internal drug-utilization review unit adjudicates the PA. Turnaround is typically 5-10 business days — faster than many PBM-based commercial plans because there's no plan/PBM/pharmacy handoff.
- If approved, the prescription is filled at a Kaiser Permanente Pharmacy (in-region) with the standard plan copay applied. Mail-order through KP's in-house mail-order pharmacy is available in every region.
If denied: KP appeal pathway
KP commercial members have a defined two-level appeal pathway plus an external review track:
- First-level internal appeal through KP Member Services. The member or the prescribing physician submits a written appeal within the timeframe stated on the denial notice (typically 180 days for commercial). KP re-reviews the PA decision with additional clinical documentation if available.
- Second-level internal appeal if the first is upheld. Often this involves a different reviewer at a higher utilization-management tier.
- External review. For California KP members (the largest KP region by far), the external review pathway is the California Department of Managed Health Care (DMHC) Independent Medical Review (IMR) — KP California is licensed under the Knox-Keene Act and is subject to DMHC oversight.[3] The IMR is binding on the plan. For non-CA regions, the external review pathway routes through the relevant state insurance regulator (CO DOI, OR DCBS, WA OIC, HI DCCA, MD MIA, VA BOI, GA DOI, DC DISB).
- If covered through an ERISA self-funded employer plan using KP as administrator (a smaller fraction of KP's book), appeals go through ERISA's federal framework and ultimately the U.S. Department of Labor — not the state IRO.
For the operational playbook on appealing dropped coverage across any payer including Kaiser, see our GLP-1 insurance dropped-coverage appeal playbook. For side effects to document during the appeal, see our GLP-1 side-effect questions hub.
If KP denies or excludes — what actually works
Ranked by cost, the practical alternatives while you appeal or if your plan permanently excludes AOMs:
- Compounded tirzepatide or semaglutide via verified 503A telehealth. Typical $149-$349/month. Not brand Wegovy or Zepbound — the active ingredient is the same, but quality and supply-chain rigor vary widely. Diligence matters.
- LillyDirect Self Pay Pharmacy single-dose vials. $299/month (2.5 mg) → $399 (5 mg) → $499 (7.5 mg) → $699 (10/12.5/15 mg) as of the December 1, 2025 price reduction. Cash-pay; no insurance involvement.
- The Zepbound OSA pathway (KP Senior Advantage). If you have a moderate-to-severe OSA diagnosis (AHI ≥15), your KP physician can submit a Zepbound PA for the OSA indication, not weight loss. Federal Part D exclusion does not apply.[6]
- Wegovy for cardiovascular risk reduction. If you have established CVD plus overweight/obesity, your KP physician can submit a Wegovy PA for the CV-risk-reduction indication. Same logic — non-weight-loss indication. [5]
- Switch payers at open enrollment. If your KP plan permanently excludes AOMs, the next open-enrollment window is the realistic option. For comparison with major commercial payers, see our Anthem GLP-1 PA guide, Aetna GLP-1 PA guide, and Does Anthem cover Zepbound for weight loss.
For mechanism-of-action context and the underlying weight- loss magnitudes (STEP-1 semaglutide -14.9% body weight at 68 weeks[7]; SURMOUNT-1 tirzepatide 15 mg -20.9% at 72 weeks[8]; SURMOUNT-2 in T2D + obesity[9]), plus the broader payer landscape, see our GLP-1 insurance coverage landscape article. Drug-specific reference data: Zepbound drug page, Wegovy drug page.
Verdict — what most Kaiser members should expect
For the median Kaiser Permanente member asking does Kaiser cover weight loss drugs: the answer is not a single national yes-or-no. It splits cleanly by indication and by plan type:
- T2D GLP-1s (Ozempic, Mounjaro, Trulicity, Victoza, Rybelsus): generally YES across all eight KP regions, with internal PA confirming the T2D diagnosis.
- Chronic-weight-management GLP-1s (Wegovy, Zepbound, Saxenda) on a KP commercial fully-insured plan: DEPENDS on region and employer tier. Check kp.org/formulary signed in to your specific plan.
- KP Senior Advantage Medicare members: NO for weight-loss-only; YES for Zepbound OSA (post-12/20/2024) and YES for Wegovy CV-risk-reduction (with KP regional PA).
- KP Medi-Cal members in California: NO for weight-loss-only as of 01/01/2026; T2D and CV-risk indications are unaffected.
- KP FEHB members: region- and tier-dependent. Request the KP FEHB regional SBC.
The integrated HMO model means the KP physician, the KP formulary committee, and the KP pharmacy are all on the same team — which can make the PA experience smoother once a drug is on-formulary, but it also means an exclusion is an exclusion at every layer simultaneously. There is no out-of-network workaround.
Disclaimer
This article is informational and does not constitute medical, financial, or legal advice. Kaiser Permanente coverage decisions are made at the regional formulary committee and employer-group level, not centrally — the authoritative source for your specific plan is the kp.org formulary search signed in to your account, the KP Member Services number on your card, and your plan's Evidence of Coverage. Quoted PA criteria, copay tiers, and timing are sourced to the primary-source documents cited below and were current as of July 2026; payer policies change frequently. Always verify with your specific plan and group number before committing to a treatment plan or paying out-of-pocket for a denial that may be appealable.
Further reading
Key terms, explained
New to GLP-1s? Tap any term for a quick, plain-English definition.
- Wegovy · Drugs and brands
- Zepbound · Drugs and brands
- Tirzepatide · Drugs and brands
- Semaglutide · Drugs and brands
- Saxenda · Drugs and brands
- Prior authorization (PA) · Insurance and regulatory
- Compounded GLP-1 · Pharmacy and drug forms
Frequently Asked Questions
References
- 1.Kaiser Permanente. Kaiser Permanente Drug Formulary — regional formulary search (Commercial / Senior Advantage / Medi-Cal / FEHB editions). Verbatim: members search by drug name, plan, and region to confirm coverage tier and PA status. kp.org/formulary. 2026.
- 2.Centers for Medicare & Medicaid Services (CMS). Social Security Act §1860D-2(e)(2)(A) — Medicare Part D excluded drugs: agents when used for the symptomatic relief of cough and colds, anorexia, weight loss, or weight gain. ssa.gov/OP_Home/ssact/title18/1860D-2.htm. 2024.
- 3.California Department of Managed Health Care (DMHC). Independent Medical Review (IMR) — external appeal pathway for Knox-Keene-licensed plans (Kaiser Foundation Health Plan CA). Decisions are binding on the plan. dmhc.ca.gov/FileaComplaint/IndependentMedicalReviewComplaintForms.aspx. 2026.
- 4.U.S. Office of Personnel Management (OPM). Federal Employees Health Benefits (FEHB) Program — prescription drug benefit standards. Plans must cover medically necessary FDA-approved drugs; AOM coverage decisions are made at the carrier/region level. opm.gov/healthcare-insurance/healthcare/plan-information. 2026.
- 5.Novo Nordisk. Wegovy (semaglutide) injection — Highlights of Prescribing Information. Indication: chronic weight management in adults and pediatric patients aged 12 and older with obesity; cardiovascular risk reduction in adults with established CVD + overweight/obesity. dailymed.nlm.nih.gov SetID ee06186f-2aa3-4990-a760-757579d8f77b. 2026.
- 6.Eli Lilly. Zepbound (tirzepatide) injection — Highlights of Prescribing Information. Indications: chronic weight management; moderate-to-severe obstructive sleep apnea in adults with obesity (12/20/2024 expansion). dailymed.nlm.nih.gov SetID 487cd7e7-434c-4925-99fa-aa80b1cc776b. 2026.
- 7.Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, et al.; STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021. PMID: 33567185.
- 8.Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, et al.; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022. PMID: 35658024.
- 9.Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, et al.; SURMOUNT-2 Investigators. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023. PMID: 37385275.
- 10.Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, et al.; SURMOUNT-OSA Investigators. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024. PMID: 38912654.
- 11.Kaiser Permanente. About Kaiser Permanente — integrated care model: Kaiser Foundation Health Plan (insurance), Kaiser Foundation Hospitals, and the Permanente Medical Groups (salaried physicians). ~12.7 million members across eight regions plus the District of Columbia. about.kaiserpermanente.org. 2026.
- 12.Kaiser Permanente. Changes for GLP-1 drugs & other Anti-Obesity Medications in 2025 (California employer notice): base coverage removed for weight-loss-only use at BMI under 40 in California commercial and Individual & Family plans, effective with contract renewal on or after January 1, 2025; optional weight loss drug rider for large groups. business.kaiserpermanente.org/business/employer/california/news-and-announcements/2024/glp-1-coverage-changes-2025 (archived copy: web.archive.org). 2024.
Related research
Kaiser Permanente GLP-1 Prior Authorization & Coverage Guide: What Kaiser Covers for Weight Loss After the January 2025 Change (2026)
Since January 2025, Kaiser Permanente no longer covers Wegovy, Zepbound, or Saxenda for weight loss alone under base coverage, though diabetes GLP-1s stay covered. Where coverage remains: a BMI gate, step therapy, a lifestyle program, 5% reauthorization, and the appeal path.
8 min read
Does Blue Cross Blue Shield Cover Weight Loss Drugs? Honest Coverage Review
Blue Cross Blue Shield is ~33 independent companies plus the FEP, with no single formulary. T2D GLP-1s are widely covered with PA; weight-loss GLP-1s vary by plan, and some Blues dropped them in 2025–2026. Medicare members may use the $50 GLP-1 Bridge.
12 min read
Health Net GLP-1 Coverage & Prior-Authorization Guide (2026)
Medi-Cal Rx dropped weight-loss GLP-1s on January 1, 2026, and Health Net commercial and Ambetter plans now require BMI plus an approved weight-loss program for prior authorization. Verbatim notices and both appeal paths.
8 min read
Does Aetna Cover GLP-1 Weight Loss Drugs? Honest Coverage Review
Aetna's pharmacy benefit is run by CVS Caremark. T2D GLP-1s are covered with PA; Wegovy, Zepbound and Foundayo for weight loss only if your employer added the AOM benefit. Zepbound returned to Caremark formularies 10/1/2026; Medicare members may qualify for the $50 GLP-1 Bridge.
11 min read
Does Humana Cover Weight Loss Drugs? Honest Coverage Review
Humana is mainly a Medicare insurer, so federal Part D law excludes weight-loss-only Wegovy, Zepbound, and Saxenda. T2D GLP-1s, Zepbound for sleep apnea, and Wegovy for heart risk or MASH are coverable with PA. The CMS GLP-1 Bridge offers $50/month since July 2026.
11 min read
Does UnitedHealthcare Cover Weight Loss Drugs? OptumRx Coverage Review
UnitedHealthcare covers type 2 diabetes GLP-1s (Ozempic, Mounjaro, Trulicity, Rybelsus) with prior authorization, but excludes weight-loss drugs under most plans unless the employer opts in. Medicare members may qualify for the $50 Medicare GLP-1 Bridge.
12 min read
Where to get tirzepatide (Mounjaro / Zepbound) safely: vetted online providers
Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.
No insurance needed · vetted by our editors
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money
HumeCare+
GLP-1 weight loss with real-time body-composition tracking to protect muscle
Read full review →From $299/mo
Get started →Collective
The lowest flat medication price if you can absorb an annual membership fee
Read full review →From $69/mo (+ required membership)
Get started →CoreAge Rx
Lowest-price compounded semaglutide and tirzepatide with one flat price at every dose
Read full review →From $129/mo (“starting at” price)
Get started →